Regulatory and funding frameworks in which medicines are made available

Overview

Medication availability and affordability are shaped by regulatory approval processes (safety/efficacy evidence review before market access) and funding/subsidy frameworks (government or insurer decisions about which medications are publicly subsidised and under what conditions) - these are distinct processes, meaning a regulatory-approved medication is not automatically affordable/accessible to patients without separate funding approval
Relevant to practical prescribing decisions across essentially all of medicine, given that a clinically appropriate, regulator-approved treatment may still be practically inaccessible to a specific patient due to funding/subsidy limitations or eligibility criteria

Funding bodies typically apply cost-effectiveness and budget-impact assessment alongside the regulator's safety/efficacy assessment, explaining why a newly approved, effective medication may not be immediately or ever publicly subsidised, or may be subsidised only for a narrower population/indication than its full regulatory approval covers

Understanding a medication's funding/subsidy status and any specific eligibility criteria (e.g. requiring specialist initiation, or failure of a specified prior treatment) should inform practical prescribing planning, since these criteria often do not align exactly with the broader clinical indication

Prescribers should be aware of funding pathway requirements (specialist authorisation, documented prior treatment failure, or other eligibility criteria) to avoid unexpected patient cost burden or treatment access delay
Where a clinically preferred medication is not funded/accessible for a specific patient, considering funded alternatives or supporting a funding exception application (where such a pathway exists) are practical management steps

Cost-effectiveness assessment as a distinct step from safety/efficacy regulatory approval, subsidy eligibility criteria narrower than full indication, specialist-initiation-only funded medications, funding exception/special access pathways

Regulatory approval and funding/subsidy approval are separate processes with separate criteria - a medication can be fully approved as safe and effective by the regulator while remaining unfunded, or funded only for a narrower population than its full approved indication, meaning prescribers need to check funding-specific eligibility separately from clinical appropriateness alone

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.